Please assess the completion status of the following clinical trial:

Trial Title: Oral Uridine for Treatment of Bipolar Depression in Adolescents

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Selection of Participants with Bipolar Disorder:~Inclusion Criteria:~* Participants must meet DSM-IV-TR (American Psychiatric Association, 2000) criteria for Bipolar Disorder Type I, Type II, or Not Otherwise Specified (NOS) with current mood state depressed for \> 2 weeks~* Participants must be between the age of 13 and 18 years~* Participants who enter the study on psychotropic medications must be on a regimen that has been stable for \> 2 weeks at the time of study entry~* Participants must be able to give informed consent or assent, and parent(s)/guardian(s) must be able to give informed permission for study participation~Exclusion Criteria:~* Adolescents with an unstable co-morbid medical, neurological, or psychiatric disorder~* Pregnant females, nursing mothers, or females of childbearing potential who are unable or unwilling to practice contraception during the study~* Participants with high risk of suicidal behaviors, homicidal behaviors, or self-harm~* Participants who in the opinion of the investigator are unlikely to be able to comply with the study protocol~* Participants who meet DSM-IV-TR criteria for current substance abuse or substance dependence, with the exception of nicotine abuse or dependence~* Participants for whom the MRI/MRS scans are contraindicated, such as children with ferromagnetic implants or claustrophobia~* Participants whose mood state is manic~* Documented or suspected history of mental retardation (IQ\<70)~* Positive urine drug screen for cocaine or amphetamines~* Known hypersensitivity to uridine~Selection of Healthy Volunteers:~Inclusion Criteria:~* Participants must be between the ages of 13 and 18 years~* Participants must not meet DSM-IV-TR diagnostic criteria for a mental disorder or substance abuse~* Participants must be able to give informed consent or assent and parents/guardians must be able to give informed permission for participation~Exclusion Criteria:~* Clinically significant medical, neurological, psychiatric or substance abuse disorder~* Pregnant subjects, due to the unknown effects of MRI/MRS scans on a fetus. In addition, women of childbearing potential who are unable or unwilling to practice contraception during the study will be excluded. Female participants who are of child-bearing potential must have a negative urine pregnancy test before each MRI/MRS scan.~* Participants with a contraindication to MRI/MRS scanning, such as a metallic implant~* Patients unable to comply with the protocol

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Uridine (Type: EXPERIMENTAL): Uridine 500 mg by mouth twice daily for 6 weeks
- Healthy Comparison (Type: NO_INTERVENTION): Healthy comparison participants were seen for baseline and week 6 MRI scans. No treatment was administered to participants enrolled as healthy comparisons.

Based on this trial design, predict the completion outcome and termination type (if applicable).